Form 4: Organon & Co. Executive Kirke Weaver Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Kirke Weaver, General Counsel & Corporate Secretary of Organon & Co., reports transactions involving common stock and derivative securities, including stock options and restricted stock units, on March 31, 2025.
Summary
- On March 31, 2025, Kirke Weaver, General Counsel & Corporate Secretary of Organon & Co., reported changes in beneficial ownership.
- These changes involve transactions in Organon & Co. common stock and derivative securities, specifically stock options and restricted stock units (RSUs).
- Weaver acquired shares through the vesting of RSUs and exercised stock options.
- Simultaneously, shares were disposed of to cover tax obligations related to the vesting of RSUs at a price of $14.51 per share.
- The reported transactions resulted in an adjusted total of 44,444 shares of common stock beneficially owned.
- Weaver also holds 181,518 stock options and 36,937 unvested RSUs.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices and insider transactions, suggesting a neutral to slightly positive sentiment due to continued equity-based incentives.
Positives
- The granting of stock options and RSUs to the reporting person aligns their interests with the long-term performance of the company.
- The vesting of RSUs indicates that performance milestones have been met, which is a positive signal.
Negatives
- The disposal of shares to cover tax obligations, while a normal occurrence, slightly reduces the reporting person's direct holdings in the company.
Risks
- Future fluctuations in the stock price could impact the value of the stock options and RSUs held by the reporting person.
- Changes in company performance or strategic direction could affect the vesting of future RSU tranches.
Future Outlook
The document outlines future vesting dates for stock options and RSUs, indicating continued equity-based compensation for the reporting person.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing is typical for executives receiving equity compensation.
Comparison to Industry Standards
- Equity compensation practices, including the use of stock options and RSUs, are common among publicly traded companies to incentivize executives.
- Vesting schedules of three years are standard in the pharmaceutical industry, aligning with long-term drug development and regulatory timelines.
- Companies like Pfizer, Merck, and Johnson & Johnson also utilize similar equity compensation structures for their executives.
Stakeholder Impact
- The transactions have a minimal direct impact on shareholders, as they primarily reflect internal compensation adjustments.
- Employees may view the equity compensation as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/31/2022 | RSUs were awarded and on March 31, 2025, the final third of these RSUs vested. |
| 11/07/2022 | RSUs were awarded and on March 31, 2025, the final third of these RSUs vested. |
| 03/31/2023 | RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026. |
| 03/29/2024 | RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. |
| 03/28/2025 | Closing market price of Organon & Co. common stock was $14.51. |
| 03/31/2025 | Date of earliest transaction and vesting of RSUs and grant of stock options and RSUs. |
| 03/31/2026 | First vesting date for new stock options and RSUs. |
| 03/31/2027 | Second vesting date for new stock options and RSUs. |
| 03/31/2028 | Final vesting date for new stock options and RSUs. |
| 04/02/2025 | Date of signature for the report. |
Keywords
Organon & Co., Kirke Weaver, beneficial ownership, Form 4, stock options, restricted stock units, RSU, common stock, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.